Hiroki Yukami

Hiroki Yukami

Auto-generated profile, based on publicly available information

Hiroki Yukami

Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2024 in Annals of Oncology
Verified
Journal Article
Open access
KKKozo Kataoka
Kozo Kataoka
KMK. Mori
K. Mori
YNY. Nakamura
Y. Nakamura
JWJ. Watanabe
J. Watanabe
NAN. Akazawa
N. Akazawa
EOEIJI OKI
EIJI OKI
The prognostic role of circulating-tumor DNA (ctDNA)-based molecular residual disease (MRD) detection and its utility for postsurgical risk-stratification has been reported in colorectal cancer. In this study, we explored the use of ctDNA-based MRD detection in patients with colorectal liver metastases (CLM), for whom the survival benefit of adjuvant chemotherapy (ACT) after surgical resection remains unclear. Patients with CLM without extrahepatic disease from GALAXY study (UMIN000039205) were included. The disease-free survival (DFS) benefit of ACT was evaluated in MRD-positive and -negative groups after adjusting for age, gender, number and size of liver metastases, RAS status, and previous history of oxaliplatin for primary cancer. ctDNA was detected using a personalized, tumor-informed 16-plex mPCR-NGS assay. ctDNA-based MRD status was evaluated 2 to 10 weeks after curative surgery, before the start of ACT. Among 6,061 patients registered in GALAXY, 190 surgically resected CLM patients without any preoperative chemotherapy were included with a median follow-up of 24 (1-48) months. ctDNA positivity in the MRD window was 32.1% (61/190). ACT was administered to 25.1% (48/190) of patients. In the MRD-positive group, 24-month DFS was higher for patients treated with ACT (33.3% vs. not reached, adjusted HR: 0.07, P <0.0001); whereas no benefit of ACT was seen in the MRD-negative group (24-month DFS: 72.3% vs. 62.2%, adjusted HR: 0.68, P =0.371). Multivariate analysis showed that the size of liver metastases (HR: 3.94, P =0.031) was prognostic of DFS in the MRD-positive group. However, in the MRD-negative group, none of the clinicopathological factors were prognostic of DFS. Our data suggest that ACT may offer notable clinical benefits in MRD-positive patients with CLM. MRD status-based risk-stratification could be potentially incorporated in future clinical trials for CLM.

9 June 2022 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
HYHiroki Yukami
Hiroki Yukami
AKAkihito Kawazoe
Akihito Kawazoe
YLYi-Tzu Lin
Yi-Tzu Lin
SKShohei Koyama
Shohei Koyama
SFShota Fukuoka
Shota Fukuoka
KSKohei Shitara
Kohei Shitara
Purpose: We previously reported preliminary activity of regorafenib plus nivolumab (REGONIVO) or lenvatinib plus pembrolizumab (LENPEM) in advanced gastric cancer (AGC). Meanwhile, several studies demonstrated liver metastases are less responsive to immunotherapy. Patients and Methods: Combined efficacy outcomes with a longer follow-up in a phase Ib trial of REGONIVO and a phase II trial of LENPEM were examined in AGC with or without liver metastases (REGONIVO plus LENPEM cohort). We also investigated the efficacy of anti-PD-1 monotherapies (anti-PD-1 monotherapy cohort). A comparison of the immune microenvironment between gastric primary tumors and liver metastases was also conducted by multiplex IHC. Results: In the REGONIVO plus LENPEM cohort, with a median follow-up of 14.0 months, objective response rate (ORR), median progression-free survival (mPFS), and median overall survival (mOS) were 46%, 7.8 months, and 15.6 months in patients with liver metastases, while 69%, 6.9 months, and 15.5 months in those without. In the anti-PD-1 monotherapy cohort, with a median follow-up of 27.6 months, ORR, mPFS, and mOS were 9%, 1.4 months, and 6.4 months in patients with liver metastases, while 22%, 2.3 months, and 9.0 months in those without. Multiplex IHC revealed liver metastases were associated with an abundance of immune-suppressive cells, such as tumor-associated macrophages and regulatory T cells, with fewer CD8+ T cells compared with gastric primary tumors. Conclusions: Anti-PD-1 antibodies plus regorafenib or lenvatinib for AGC showed promising antitumor activity with a longer follow-up, irrespective of liver metastases status, despite a more immune-suppressive tumor microenvironment in liver metastases.

28 July 2022 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
TMTakao Morinaga
Takao Morinaga
TITakashi Inozume
Takashi Inozume
MKMasahito Kawazu
Masahito Kawazu
YUYouki Ueda
Youki Ueda
NSNicolas Sax
Nicolas Sax
YTYosuke Togashi
Yosuke Togashi
Some patients experience mixed response to immunotherapy, whose biological mechanisms and clinical impact have been obscure. We obtained two tumor samples from lymph node (LN) metastatic lesions in a same patient. Whole exome sequencing for the both tumors and single-cell sequencing for the both tumor-infiltrating lymphocytes (TIL) demonstrated a significant difference in tumor clonality and TILs’ characteristics, especially exhausted T-cell clonotypes, although a close relationship between the tumor cell and T-cell clones were observed as a response of an overlapped exhausted T-cell clone to an overlapped neoantigen. To mimic the clinical setting, we generated a mouse model of several clones from a same tumor cell line. Similarly, differential tumor clones harbored distinct TILs, and one responded to programmed cell death protein 1 (PD-1) blockade but the other did not in this model. We further conducted cohort study (n = 503) treated with PD-1 blockade monotherapies to investigate the outcome of mixed response. Patients with mixed responses to PD-1 blockade had a poor prognosis in our cohort. Particularly, there were significant differences in both tumor and T-cell clones between the primary and LN lesions in a patient who experienced tumor response to anti–PD-1 mAb followed by disease progression in only LN metastasis. Our results underscore that intertumoral heterogeneity alters characteristics of TILs even in the same patient, leading to mixed response to immunotherapy and significant difference in the outcome.Significance: Several patients experience mixed responses to immunotherapies, but the biological mechanisms and clinical significance remain unclear. Our results from clinical and mouse studies underscore that intertumoral heterogeneity alters characteristics of TILs even in the same patient, leading to mixed response to immunotherapy and significant difference in the outcome.

13 December 2018 in Asia-Pacific Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
HYHiroki Yukami
Hiroki Yukami
TTTetsuji Terazawa
Tetsuji Terazawa
MGMasahiro Goto
Masahiro Goto
MAMasahiko Aoki
Masahiko Aoki
KAKen Asaishi
Ken Asaishi
KHKazuhide Higuchi
Kazuhide Higuchi

31 March 2023
Verified
Other
Open access
HYHiroki Yukami
Hiroki Yukami
AKAkihito Kawazoe
Akihito Kawazoe
YLYi-Tzu Lin
Yi-Tzu Lin
SKShohei Koyama
Shohei Koyama
SFShota Fukuoka
Shota Fukuoka
KSKohei Shitara
Kohei Shitara
Supplementary Figure from Updated Efficacy Outcomes of Anti-PD-1 Antibodies plus Multikinase Inhibitors for Patients with Advanced Gastric Cancer with or without Liver Metastases in Clinical Trials

31 March 2023
Verified
Other
Open access
HYHiroki Yukami
Hiroki Yukami
AKAkihito Kawazoe
Akihito Kawazoe
YLYi-Tzu Lin
Yi-Tzu Lin
SKShohei Koyama
Shohei Koyama
SFShota Fukuoka
Shota Fukuoka
KSKohei Shitara
Kohei Shitara
Supplementary Table from Updated Efficacy Outcomes of Anti-PD-1 Antibodies plus Multikinase Inhibitors for Patients with Advanced Gastric Cancer with or without Liver Metastases in Clinical Trials